Remembering Jean-Francois Bach
Jean-Francois Bach, MD, DSc 1940-2023
Latest News
New Publication from CATNIP Trial: Anti-TSLP Plus Antigen-Specific Immunotherapy For Induction Of Tolerance In Individuals With Cat Allergy
The CATNIP trial– a double blind randomized placebo controlled trial – tested whether treating cat allergy tested whether giving a monoclonal antibody called tezepelumab, which interferes with TSLP signaling, plus cat allergy shots to people with allergic rhinitis caused by cat allergens would safely provide better and longer-lasting s
Request For Proposal: Mechanistic Assays on Stored Samples from the GRASS Trial
Olivia Doyle
Mon, 2022-02-14 17:37
The Immune Tolerance Network is currently requesting proposals for the supplementary mechanistic analyses for the remaining participant samples from the Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial.
New Publication from IMPACT Trial: Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy
Olivia Doyle
Mon, 2022-01-24 20:53
The IMPACT trial – a double blind randomized placebo controlled study – was designed to test whether young, peanut allergic children (12-48 months) could be desensitized with peanut oral immunotherapy (OIT) and ultimately remain non-responsive to peanut after discontinuation of OIT.
New Publication from EXTEND Trial: IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes
The EXTEND trial was a double blind randomized placebo controlled study designed to test the effect of IL-6 receptor blockade (tocilizumab) in pediatric participants (age 6-17 years) with new onset type 1 diabetes. IL-6 pathway blockade is an effective immunotherapy in some autoimmune diseases including juvenile idiopathic arthritis and rheumatoid arthritis working, at
ITN’s Christian Larsen, MD, DPhil, presented with AMA Scientific Achievement Award
Christian P. Larsen, MD, DPhil, the Immune Tolerance Network’s (ITN’s) deputy director in transplantation, transplant surgeon, and immunologist was presented with the 2021 American Medical Association (AMA) Scientific Achievement Award.
New Publication: Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis
The PAUSE trial was conducted to determine whether blocking CD28/B7 costimulatory signaling with abatacept would prevent relapse of psoriasis after effective treatment with ustekinumab (an IL12/23 antagonist).
New Publication: Approaches to Establishing Tolerance in Immune Mediated Diseases
In an article published today in Frontiers in Immunology, Immune Tolerance Network (ITN) leadership and clinical trial physicians review ITN's approach to the development of therapies that aim to establish tolerance in immune mediated diseases.
Allergy, Asthma and COVID-19 Susceptibility
In a study published on April 22, 2020 in JACI, data from ITN’s CATEEC clinical trial was used to investigate the connection between asthma and allergic disease and the novel coronavirus, SARS-
ITN’s CATEEC Article Selected as Editor’s Choice Feature by JACI
The ITN article that reported the results of the CATEEC clinical trial, which compared clinical and biological responses to cat allergen exposure by nasal allergen challenge (NAC) or environmental exposure chamber (EEC) was selected to be an Editors’ Choice feature and was displayed on the American Academy of Allergy Asthma & Immunology (AAAAI) website.